#1a 00 HEALTHCARE CELLTRION May 2021 Celltrion Healthcare 1Q21 Earnings Presentation#2HEALTHCARE CELLTRION Contents Section 01. 1Q21 Business Results Section 02. Key Business Performance Appendix#3Section 01 1Q21 Business Results HEALTHCARE CELLTRION#41Q21 Business Results Income Statement Revenue Rise in sales of Remsima", Herzuma®, and RemsimaⓇ SC offset temporary decrease in US sales attributable to shipment schedule ▶ OP : Decreased QoQ as a result of a scheuled decline in high-margin US TruximaⓇ sales as well as rises in SG&A for direct sales NP Recorded similar net profit YoY with increases in non-operating profit as won weakened compared to the previous quarter (KRW bn) '20.1Q '20.4Q '21.1Q % YoY %QoQ Revenue 356.9 387.0 356.3 -0.2% -7.9% Gross Profit 94.5 145.0 82.3 -12.9% -43.2% (%) 26.5% 37.5% 23.1% -3.4%p -14.4%p SG&A 38.7 53.3 50.8 31.3% -4.7% (%) 10.8% 13.8% 14.3% 3.5%p 0.5%p Personnel expenses 6.8 16.9 12.8 88.2% -24.3% Research expenses 6.4 7.9 9.8 53.1% 24.1% Advertising expenses 2.5 2.4 1.4 -44.0% -41.7% Commissions 9.4 13.7 13.4 42.6% -2.2% Operating Profit 55.8 91.8 31.5 -43.5% -65.7% (%) 15.6% 23.7% 8.8% -6.8%p -14.9%p EBIT 98.2 27.2 35.0 -64.4% 28.7% Net Profit 76.2 31.7 31.5 -58.7% -0.6% Investor Relations 2021 4#51Q21 Business Results By Product (Unit: KRW bn) By Region Sales Breakdown (Unit: KRW bn) 387.0 387.0 -1% 356.9 2% 356.3 356.9 356.3 2% 9% -1% 15% 5% 7% 10% 20% 17% 49% 46% 48% 31% 51% 28% 52% 42% 46% 39% 45% 34% '20.1Q '20.4Q '21.1Q '20.1Q '20.4Q '21.1Q Remsima / Inflectra Truxima Remsima SC Others Herzuma Europe N. America Others Investor Relations 2021 5#61Q21 Business Results Balance Sheet Cash Flow Balance Sheet & Cash Flow (KRW bn) '20 '21.1Q Change (KRW bn) '20 '21.1Q Cash at beginning of year 297.0 231.5 Total Assets 3,739.7 3,766.0 26.3 Operating -16.9 -0.6 Cash and Cash 231.5 Operating profit 362.1 31.5 290.4 58.9 Equivalents Working capital -384.6 -31.3 Short Term 295.7 260.9 -34.8 Others 5.6 -0.8 Financial Assets Investing -136.2 36.9 Trade and Other Receivables 409.8 345.6 -64.2 Short term financial assets -132.5 35.7 Others -3.7 1.2 Inventories 2,034.6 2,118.3 83.7 Financing 87.6 22.6 Total Liabilities 1,806.8 1,793.5 -13.3 Borrowing and redemption 80.1 21.5 Share buyback -2.9 0.0 Total Equity 1,932.9 1,972.5 39.6 Share issue 12.9 1.8 Others -2.5 -0.7 Debt-to-Equity Ratio 93.5% 90.9% -2.6%p Cash at the end of year 231.5 290.4 Investor Relations 2021 6#7Section 02 Key Business Performance HEALTHCARE CELLTRION#8Key Business Performance RemsimaⓇ & InflectraⓇ ✓ Infliximab market leader in major EU countries including EU5(market share 59%) ✓ Accelerating market share uptake in the US as Remicade® has been excluded from the United Healthcare's preferred drug list since Feb.2021 Market share of RemsimaⓇ/ InflectraⓇ in Europe Market share of InflectraⓇ in the US & RemsimaⓇ in Japan 100% 90% 80% 70% 60% 50% 15% 14% 11% 12% 10% 8% 9% 6% 5% 6% 4% 2% 3% 0% 59% 60% 57% 0% 54% 55% 52% 53% 17.1Q 3Q 18.1Q 3Q 19.1Q 3Q 20.1Q 3Q 21.1Q 46% Inflectra® (US) 37% 20% 19% 40% 16% 28% 30% 18% 15% 12% 10% 20% 9% 10% 10% 8% 7% 6% 5% 4% 5% 3% 1% 0% 0% 15.2Q 4Q 16.2Q 4Q 17.2Q 4Q 18.2Q 4Q 19.2Q 4Q 20.2Q 4Q 16.1Q 3Q 17.1Q 3Q 18.1Q 3Q 19.1Q 3Q 20.1Q 3Q 21.03 Remsima / Inflectra® Remicade Remsima® (Japan) Note: market share is based on volume Source: IQVIA Note: market share is based on volume Source: Symphony Health, IQVIA Investor Relations 2021 8#9Key Business Performance TruximaⓇ ✓ Maintaining the highest market share(41%) in EU5 comparing to the original (27%) and competitor(31%) ✓ Expecting the gradual expansion of market share while retaining high profitability in the US Market share of TruximaⓇ in Europe 100% 90% 80% 70% 60% 50% 40% 30% 18% 20% Market share of TruximaⓇ in the US 100% 90% 80% 70% 60% 25% 38% 39% 36% 37% 36% 20% 31% 15% 10% 6% 14% 22% 20% 20% 5% 1% 10% 2% 0% 0% 19.4Q 20.1Q 2Q 3Q 4Q 21.1Q 17.2Q 4Q 18.2Q 4Q 19.2Q 4Q 20.2Q 4Q TruximaⓇ Rituxan® A Biosimilar TruximaⓇ RixutanⓇ B Biosimilar Note: market share is based on volume Source: IQVIA Note: market share is based on unit Source: Symphony Health Investor Relations 2021 9#10Key Business Performance Herzuma ✓ Retaining the highest market share among HerceptinⓇ biosimilars launched in EU while securing profitability by strategically participating in tenders ✓ Showing rapid penetration since the approval of 3-weekly regimen for breast cancer in Japan Market share of HerzumaⓇ in Europe Market share of HerzumaⓇ in Japan 100% 90% 80% 70% 60% 20% 15% 100% 80% 60% 19% 19% 18% 40% 16% 16% 15% 15% 13% 10% 47% 44% 39% 35% 25% 20% 10% 19.08 approval of 3-weekly regimen 12% 4% 5% 2% 1% 0% 0% 0% 0% 18.1Q 2Q 3Q 4Q 19.1Q 2Q 3Q 4Q 20.1Q 2Q 3Q 4Q 19.2Q 3Q 4Q 20.1Q 2Q 3Q 4Q 21.03 HerzumaⓇ Herceptin C Biosimilar D Biosimilar Note: market share is based on volume Source: IQVIA Note: market share is based on volume Source: IQVIA Herzuma® HerceptinⓇ Investor Relations 2021 10#11Key Business Performance ✓ Completed launching in more than 70% of EU market including EU5 countries by 1Q21 RemsimaⓇ SC ✓ Aiming to expand the market entry by launching other global markets such as Canada and Australia this year Current Status Launching plan in Canada & Australia Launched to more than 70% of the entire EU Market Launched Completed launching in France, Spain, and Italy in 1021 H TNF-α Expand target market Planning to launch to other global markets $1.8bn $317mn Market Size Aiming to expand regions by launching in other global markets such as Canada and Australia Approval Jan. 2021 Dec. 2020 Direct Induction Received positive CHMP opinion for direct use of Subcutaneous therapy without IV loading with RA patients (for Rheumatoid Arthritis) - The Committee for Medicinal Products for Human USE(CHMP) of the European Medicines Agency(EMA) has recommended RemsimaⓇ SC for direct use of subcutaneous therapy without IV loading in adults with rheumatoid arthritis (RA) Launching Timeline Note: market size is as of 2020 Source: IQVIA 2Q21 3Q21 Investor Relations 2021 11#12Key Business Performance ✓ Won approval of EMA in Feb.2021 and will start launching in EU in 2Q21 going forward ✓ Value proposition as the only high-concentration biosimilar with high price competitiveness Market size of Adalimumab in EU 100% 4% 10% 14% 75% EU Adalimumab 50% 45% Market Size $4.0bn 55% ■low-concentration ■high-concentration Note: market size is as of 2020 Source: IQVIA 16% 56% 25% Yuflyma Aiming to launch YuflymaⓇ in more than 70% of the EU Adalimumab market in 2021 '21.2Q(E) 6 countries including Spain (16% among EU Adalimumab market) '21.3Q(E) 7 countries including France, Germany (45%) 3 countries '21.4Q(E) including 0% Italy (11%) HumiraⓇ HyrimozⓇ AmgevitaⓇ ImraldiⓇ Hulio® Note: market size is as of 2020 Source: IQVIA Investor Relations 2021 12#13Appendix HEALTHCARE CELLTRION#14Pipeline ✓ Aiming to launch at least 1 biosimilar every year by 2030 Product Name Reference Drug Manufacturer Indications Global Market size ($bn) US RemsimaⓇ SC Celltrion Autoimmune Disease 48.5 In Phase 3 EU All Indication Approved (Jul.2020, Pediatric usage non-included) Received European Commission Approval (Feb.2021) In Global Phase 3 Clinical Trials (Aiming to complete by 1H21) YuflymaⓇ HumiraⓇ (Adalimumab) AbbVie Autoimmune Disease Preparing Application 30.4 Submission CT-P16 Avastin® (Bevacizumab) Roche Colorectal Cancer, etc. 6.1 CT-P39 XolairⓇ (Omalizumab) Allergic Asthma, Genentech 3.3 CIU In Global Phase 3 Clinical Trials (Jul.2020~) CT-P43 StelaraⓇ (Ustekinumab) Johnson & Johnson Autoimmune 10.9 Disease In Global Phase 3 Clinical Trials (Sep.2020~) CT-P41 ProliaⓇ (Denosumab) Amgen Osteoporosis 5.2 In Global Phase 3 Clinical Trials (Sep.2020~) CT-P42 EyleaⓇ (Aflibercept) Bayer & Regeneron Macular Degeneration 6.1 In Global Phase 3 Clinical Trials (Jan.2021~) Note: global market size is as of 2020 Source: IQVIA Investor Relations 2021 14#15Summary Income Statement (KRW bn) 1Q18 2Q18 3Q18 4Q18 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 '17 '18 '19 '20 Revenue 128.4 183.8 212.7 188.7 220.5 284.8 282.0 313.6 356.9 420.3 463.4 387.0 356.3 920.9 713.5 1,100.9 1,627.6 Cost of Sales 102.8 144.9 168.8 228.1 186.6 248.3 233.1 223.5 262.4 292.0 289.4 242.0 274.0 696.8 644.6 891.6 1,085.8 Gross Profit 25.6 38.8 43.9 (39.4) 33.9 36.4 48.9 90.1 94.5 128.3 174.0 145.0 82.3 224.1 68.9 209.3 541.8 SG&A 17.1 23.6 23.8 29.5 24.5 27.2 27.6 47.2 38.7 41.4 46.3 53.3 50.8 70.5 94.1 126.5 179.7 Operating Income (Loss) 8.4 15.2 20.0 (68.9) 9.4 9.3 21.3 42.8 55.8 86.8 127.7 91.8 31.5 153.7 (25.2) 82.8 362.1 Non-operating 74.1 0.7 (11.0) (14.2) (0.8) 8.7 5.1 (19.8) 42.4 (18.1) (7.0) (64.5) 3.6 52.5 49.6 (6.7) (47.2) Income Financial Income 74.2 10.5 (6.3) (6.2) 4.9 6.8 7.3 1.0 22.8 3.6 3.1 9.2 5.5 114.6 70.5 20.0 38.7 Financial Expenses 6.4 4.7 3.4 0.6 5.1 13.6 5.9 4.9 7.4 16.9 8.2 1.4 12.5 47.1 13.3 29.5 33.9 Other Income 11.0 0.9 4.0 0.9 2.1 16.3 10.2 (7.8) 32.5 11.7 7.4 (13.2) 27.0 16.8 14.2 20.8 38.4 Other Expenses 4.7 6.0 5.3 8.4 2.6 0.8 6.5 8.1 5.5 16.5 9.3 59.1 16.4 31.8 21.7 18.0 90.4 Profit (Loss) before 82.5 16.0 9.1 (83.1) 8.6 18.0 26.4 22.4 98.2 68.7 120.6 27.2 35.0 206.1 24.4 75.4 314.7 Taxes Tax Expense 22.0 5.0 2.7 (16.5) 2.8 9.5 16.3 (18.2) 22.0 22.2 34.5 (4.4) 3.5 48.7 13.0 10.4 74.3 (Benefit) Net Profit (Loss) 60.5 11.0 6.4 (66.6) 5.8 8.5 10.1 40.6 76.2 46.4 86.1 31.7 31.5 157.4 11.4 65.0 240.4 Investor Relations 2021 15#16Thank You HEALTHCARE CELLTRION